TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06038552

Intervention type: DRUG
Intervention: imatinib (IM)
Description: Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.

Intervention type: DRUG
Intervention: imatinib (IM)
Description: Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.

Intervention type: DRUG
Intervention: imatinib (IM)
Description: Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.

Intervention type: PROCEDURE
Intervention: hepatic resection (HR)
Description: HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.

Intervention type: PROCEDURE
Intervention: radiofrequency ablation (RFA)
Description: RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
Study: NCT02048982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cost
Description: Physicians will receive cost information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Victim
Description: Physicians will receive information on an identifiable victim.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Victim
Description: Physicians will receive information on an identifiable victim.
Study: NCT01425216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
Study: NCT01452542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, common blend proposed commercial formulation
Description: All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, common blend proposed commercial formulation
Description: All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, Phase 3 capsule formulation
Description: All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, Phase 3 capsule formulation
Description: All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
Study: NCT06038552

Intervention type: PROCEDURE
Intervention: transarterial chemoembolization (TACE)
Description: TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
Study: NCT04304703

Intervention type: DEVICE
Intervention: WHOOP strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
Study: NCT01449084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate stent removal
Description: The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Leaving the stent in place
Description: The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE
Study: NCT01843231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: g-CathTM EZ Suture Anchor Delivery Catheter
Description: Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise Control Group
Description: Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
Study: NCT01459029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-serine
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Study: NCT03084627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored dietary advice
Description: The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
Study: NCT02981576

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
Study: NCT02327715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
Study: NCT02622334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo formulation will be administered in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
Study: NCT01533129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testogel 50 mg transdermal gel
Description: 50mg testosterone gel implementation on every night

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 250mg injection
Description: The testosterone 250mg ester IM injections performed in three weeks.
Study: NCT03176342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patch test
Description: Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
Study: NCT03874481

Intervention type: OTHER
Intervention: Observation
Description: follow up regularly for MACE
Study: NCT02262312

Intervention type: OTHER
Intervention: Transient elastography
Description: All patients will have a transient elastography performed as a measure of liver stiffness.
Study: NCT02319382

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET with the tracer 18F-DPA-714

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET with the tracer 11C-PE2I

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic field
Study: NCT01428245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace (estrogen)
Description: oral estrace, 0.5-1 mg once a day for seven days
Study: NCT00759096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTOR IOL Model SA60D3
Description: Implanted into the study eye following cataract extraction surgery
Study: NCT02115477

Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Pelvic and/or paraaortic lymphadenectomy
Study: NCT01529996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Dye Laser/YAG laser
Description: This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Dye Laser/YAG laser
Description: This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
Study: NCT01911338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Time Feedback
Description: Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
Study: NCT01221909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 5cc saline solution
Study: NCT01911338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Learning Method
Description: Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
Study: NCT02981641

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy
Description: Sequential chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy
Description: Sequential chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three dimensional conformal radiation therapy (3D-CRT)
Description: Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
Study: NCT01935804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg/daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg/daily for 12 months
Study: NCT03731143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of self retaining bicanalicular stent
Description: The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti
Study: NCT02562469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVATE
Description: A home-based computerized brain training intervention for youth.
Study: NCT02898571

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparitor

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Active treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: epicatechin
Description: Active treatment
Study: NCT01266720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1, VEGFR2
Description: One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
Study: NCT00729222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: rolofylline placebo IV infusion over 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV infusion over 4 hours.
Study: NCT04076553

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Participants will complete 12 sessions of CBT

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CBT
Description: Participants will complete 12 sessions of CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICT
Description: Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12
Study: NCT03630601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI
Study: NCT04373733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Anti-viral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care management
Description: Standard of care management for COVID-19

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care management
Description: Standard of care management for COVID-19
Study: NCT03033628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection using DentalVibe comfort system
Description: giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
Study: NCT00520130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic stem cell transplant (ASCT)
Description: Allogenic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Chemotherapy
Description: Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3
Study: NCT03033628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional dental injection
Description: giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
Study: NCT01044199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCEC rabies vaccine given intradermally
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCEC rabies vaccine given intradermally
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCEC rabies vaccine administered intramuscularly
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCEC rabies vaccine administered intramuscularly
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
Study: NCT01751685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis-specific spinal strengthening exercises
Description: Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: monthly educational lectures on various topics
Study: NCT04625972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2 IM injections) of saline placebo on Day 1.
Study: NCT01859091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT02390388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal nerve block
Description: nerve stimulator-guided Pudendal block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block
Study: NCT02069184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline as placebo
Description: 100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
Study: NCT01463345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels \>7.5 g/dl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels \> 9.0 g/dl.
Study: NCT04864769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill protein hydrolysate
Description: Ingestion of 35 g Krill protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein isolate
Description: Ingestion of 35 g Soy protein isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Ingestion of 35 g Whey protein isolate
Study: NCT04704804

Intervention type: DIAGNOSTIC_TEST
Intervention: Synthetic CT Scan
Description: method of generating CT-synthetic image from MRI
Study: NCT04864769

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Ingestion of water (control)
Study: NCT04267042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal Atomization Device
Description: MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation
Description: INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.